EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC

Marion Caumeil iD, Julie A Vendrell, Simon Cabello-Aguilar iD, Sarah Cavaillon iD, Quentin Dominique Thomas, Jérôme Solassol iD

Thoracic Cancer · 2026-08 · 17 (15)

DOI: 10.1111/1759-7714.70313 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, online erschienen am 29.07.2026. Verfasst von Marion Caumeil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Biologie des Tumeurs Solides, CHU Montpellier, Université de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Circulating Tumor DNA. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) monitoring may detect resistance to KRAS G12C inhibitors earlier than conventional imaging. However, in the specific context of KRAS G12C inhibitors, the temporal relationship between molecular, radiologic, and clinical progression remains poorly characterized. A 66‐year‐old woman with KRAS G12C / STK11 / KEAP1 ‐mutant lung adenocarcinoma received second‐line adagrasib after progression on chemo‐immunotherapy. Serial ctDNA monitoring by droplet digital PCR and targeted next‐generation sequencing was performed. Baseline KRAS G12C ctDNA (6205.3 copies/mL) declined to 3.2 copies/mL after 7 weeks, indicating initial response. However, ctDNA levels rose to 21.1 copies/mL at month 4 and 315.2 copies/mL at month 6. Concurrent NGS revealed three emergent KRAS mutations (G12D, G13D, Q61H), confirming polyclonal resistance. Notably, CT and MRI imaging remained stable by RECIST criteria throughout this period. Significant clinical deterioration, requiring prolonged hospitalization, occurred approximately 8 weeks after initial ctDNA rise. The patient died 2 months after detection of resistance mutations. In this case, NGS ctDNA detected three acquired KRAS resistance mutations in addition to the original G12C, during a prolonged period of radiographic stability, illustrating polyclonal evolution under adagrasib pressure. These findings suggest that longitudinal liquid biopsy monitoring may provide early detection of resistance in KRAS G12C ‐mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungProto-Oncogene Proteins p21(ras)Circulating Tumor DNADrug Resistance, NeoplasmAcetonitrilesPiperazinesPyrimidinesAntineoplastic AgentsHumansFemaleAgedMutationFatal OutcomeLiquid BiopsyDrug Monitoring

Stichwörter der Autor:innen

KRAS G12Cacquired resistanceadagrasibcirculating tumor DNAliquid biopsynon‐small cell lung cancer

Substanzen

adagrasibAcetonitrilesPiperazinesPyrimidinesAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)Circulating Tumor DNA

Autor:innen und Institutionen

  • Laboratoire de Biologie des Tumeurs Solides, CHU Montpellier, Université de Montpellier, Montpellier, France.
  • MOBIDIC, Montpellier, France.
  • Institut du Cancer de Montpellier (ICM), Montpellier, France.
  • Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.

ORCID-Profile: Marion Caumeil, Simon Cabello-Aguilar, Sarah Cavaillon, Jérôme Solassol

Zitieren

APA

Caumeil, M., Vendrell, J. A., Cabello-Aguilar, S., Cavaillon, S., Thomas, Q. D., & Solassol, J. (2026). ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC. Thoracic Cancer, 17(15). https://doi.org/10.1111/1759-7714.70313

Vancouver

Caumeil M, Vendrell JA, Cabello-Aguilar S, Cavaillon S, Thomas QD, Solassol J. ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC. Thoracic Cancer. 2026;17(15). doi:10.1111/1759-7714.70313

BibTeX
@article{Caumeil2026,
  author = {Caumeil, Marion and Vendrell, Julie A and Cabello-Aguilar, Simon and Cavaillon, Sarah and Thomas, Quentin Dominique and Solassol, Jérôme},
  title = {ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {15},
  doi = {10.1111/1759-7714.70313}
}
Kostenlos starten →